Literature DB >> 32389770

Hip Arthroscopy for Femoroacetabular Impingement and Concomitant Labral Tears: A Minimum 2-Year Follow-Up Study.

Jun-Ki Moon1, Jae Youn Yoon1, Chul-Ho Kim1, Sunhyung Lee2, Aditya L Kekatpure1, Pil Whan Yoon3.   

Abstract

PURPOSE: The present study investigated the minimum 2-year outcomes of hip arthroscopy for femoroacetabular impingement (FAI) and concomitant labral tears in Asian patients.
METHODS: Patients who underwent hip arthroscopy for both FAI and concomitant labral tears between January 2012 and December 2017 were included. Patients with hip osteoarthritis of Tönnis grade ≥2, previous hip surgery, or followed for less than 2 years were excluded. Clinical assessments were performed using the modified Harris Hip Score, Western Ontario and McMaster Universities Osteoarthritis Index, and the rates of achieving threshold values of the minimal clinically important difference and patient acceptable symptomatic state at the latest follow-up. Plain radiographs were acquired pre- and postoperatively for radiologic assessments.
RESULTS: A total of 73 patients (90 hips, 58 male, 15 female; mean age 34.4 years) who underwent hip arthroscopy for FAI and concomitant labral tears were enrolled. Forty-three hips (47.8%) had cam-type, 7 (7.8%) had pincer-type, and 40 (44.4%) had mixed-type FAI. The mean follow-up duration was 5.2 years. In cam- and mixed-type FAI hips, the mean α angle significantly decreased from 66.7 ± 8.28° preoperatively to 44.9 ± 3.78° postoperatively (95% confidence interval [CI] 19.6°-22.8°; P < .001). The mean modified Harris Hip Score and Western Ontario and McMaster Universities Osteoarthritis Index increased from 74.8 ± 13.2 and 75 ± 12.7 preoperatively to 93 ± 8.1 (95% CI 15.4-20.9; P = .001) and 89.4 ± 8.4 postoperatively (95% CI 11.8-17; P = .001), respectively. Seventy-four hips (82.2%) crossed the minimal clinically important difference, and 85 hips (94.4%) had achieved the patient acceptable symptomatic state. There were 2 cases of pudendal nerve palsy and 1 case of sciatic nerve palsy. No additional surgeries were required.
CONCLUSIONS: Hip arthroscopy can be an effective treatment for FAI and concomitant labral tears in Asian patients as demonstrated in this study, with improved PRO scores and reoperation rates. Longer-term studies with larger cohorts are necessary. LEVEL OF EVIDENCE: Level IV, case series.
Copyright © 2020 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32389770     DOI: 10.1016/j.arthro.2020.04.041

Source DB:  PubMed          Journal:  Arthroscopy        ISSN: 0749-8063            Impact factor:   4.772


  4 in total

1.  Hip arthroscopy for femoroacetabular impingement is associated with significant improvement in early patient reported outcomes: analysis of 4963 cases from the UK non-arthroplasty registry (NAHR) dataset.

Authors:  Richard Holleyman; Mark Andrew Sohatee; Stephen Lyman; Ajay Malviya; Vikas Khanduja
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2022-07-14       Impact factor: 4.114

2.  Top Ten Pearls for Successful Hip Arthroscopy for Femoroacetabular Impingement.

Authors:  Allison K Perry; Steven F DeFroda; Safa Gursoy; Iain R Murray; Amar S Vadhera; Shane J Nho; Jorge Chahla
Journal:  Arthrosc Tech       Date:  2021-07-21

3.  There is no definite consensus on the adequate radiographic correction in arthroscopic osteochondroplasty for femoroacetabular impingement: a systematic review and meta-analysis.

Authors:  Dan Cohen; Abdullah Khan; Jeffrey Kay; David Slawaska-Eng; Mahmoud Almasri; Nicole Simunovic; Andrew Duong; Marc R Safran; Olufemi R Ayeni
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-06-26       Impact factor: 4.114

4.  Cam Impingement of the Knee: Arthroscopic Correction of Posteromedial Tibiofemoral Incongruence.

Authors:  Konrad Malinowski; Magdalena Koźlak; Marcin Mostowy; Robert F LaPrade; Michał Ebisz; Przemysław A Pękala
Journal:  Arthrosc Tech       Date:  2022-05-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.